Merrimack Pharmaceuticals, Inc. MACK NASDAQ

Merrimack Pharmaceuticals, Inc. (MACK) reported total assets of $244.32M and total liabilities of $22.67M for quarter ending 2024-03-31, resulting in total equity of $221.65M.

The company held $244.11M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-234.16M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 10.78, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 10.78 — balance sheet is strong
• MOAT (28/100) — Total assets $244.32M and equity $221.65M support the company's competitive scale

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.